Portola Pharmaceuticals
"Having been in biotech 14 years, one always needs to do two things," says Portola Pharmaceuticals CEO Charles Homcy. "One is being cautious and looking at the things outside of our control, watching the money. And the other thing that is important is clinical data. Nothing is more important than good clinical data. What we're focusing on right now is protecting the portfolio by keeping it well funded without diluting equity."
And a cash-hungry Portola is busy at work getting that data while lining up partners for some of its development programs to keep the money coming in. Article